Publications Pharmacogenotyping

2023

Bollinger A, Stäuble CK, Jeiziner C, Wiss FM, Hersberger KE, Lampert ML, Meyer zu Schwabedissen HE, Allemann SS. Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study. Pharmgenomics Pers Med. 2023;16:693-706. https://doi.org/10.2147/PGPM.S415259

Jeiziner, C., Meyer zu Schwabedissen, H.E., Hersberger, K.E. et al. Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service. Int J Clin Pharm (2023). https://doi.org/10.1007/s11096-023-01596-8

2022

Wittwer, Nina L., et al. "Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database." Pharmacogenomics and Personalized Medicine 15 (2022): 967-976. https://www.dovepress.com/utilization-of-drugs-with-pharmacogenetic-dosing-recommendations-in-sw-peer-reviewed-fulltext-article-PGPM

Stäuble CK, Jeiziner C, Bollinger A, Wiss FM, Hatzinger M, Hersberger KE, Ihde T, Lampert ML, Mikoteit T, Meyer zu Schwabedissen HE, Allemann SS. A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting. Pharmacy. 2022; 10(4):86. https://doi.org/10.3390/pharmacy10040086

Stäuble, C.K., et al. "Case Report: Non-Response to Fluoxetine in a homozygous 5-HTTLPR S-Allele Carrier of the Serotonin Transporter Gene." Frontiers in Psychiatry: 1590. https://doi.org/10.3389/fpsyt.2022.942268

Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE. Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report. Pharmgenomics Pers Med. 2022;15:465-475. https://doi.org/10.2147/PGPM.S354011

2021

Stäuble, Céline K., et al. "Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial." Trials 22.1 (2021): 1-11.

Jeiziner C, Wernli, U, Suter K, Hersberger KE, Meyer zu Schwabedissen HE. HLA-associated adverse drug reactions - scoping review. Clin Transl Sci  2021. DOI: 10.1111/cts.13062. Publication

Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE. Enriching medication review with a pharmacogenetic profile – a case of tamoxifen adverse drug reactions. Pharmgenomics Pers Med Vol. 24. DOI 10.2147/PGPM.S285807. Publication

Archiv

Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE. Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. Pharmacogenomics Vol. 21, No 16. DOI: 10.2217/pgs-2020-0087. Publication

Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M, Klein TE, Szucs TD, Hersberger KE, Meyer zu Schwabedissen HE. Pharmacogenetic information in Swiss drug labels – a systematic analysis. Pharmacogenomics J 2020. DOI: 10.1038/s41397-020-00195-4. Publication